drugset / Trial / NCT06138275
Elranatamab in R/R Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This research is being done to see if the study drug, elranatamab, reduces the risk of disease progression (worsening disease) after idecabtagene vicleucel in relapsed refractory multiple myeloma.
Timeline
- Start
- 2024-03-08
- Primary completion
- 2027-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Elranatamab | Monoclonal antibody | — | Subcutaneous |